P2T designs so called phase 2 studies to answer a simple question: the ‘Null Hypothesis”. The null hypothesis can be confirmed or rejected on the basis of previously defined objective endpoints. For example: a new treatment, that generates in at least 1 out of 3 patients a measurable improvement and has no or only rarely serious side effects will be used in future clinical studies.

New treatments with too many side effects and with insufficient improvement in patients- that is less than 1 out of three patients, will be excluded from further studies, but will be published in the open medical literature.

We invite academic clinical-medical investigators to collaborate with us in P2T projects. Two principal investigators will lead each project: one employee of the academic institute and one P2T member.

If you are interested in participating in a P2T project, please contact us.

BSA Versus BW

BSA versus BW

Define the highest possible therapeutic ratio for prescribing cancer chemotherapy, based on prescription units as body weight and body surface area.

read more
Tapering Strip Anti-depressants

Tapering strip anti-depressants

Research as to the utility of a ‘tapering strip’ for a slow stepwise stopping of taking antidepressants.

read more
Radiated Blood

Radiated blood

P2T has improved the logistics of blood irradiation by constructing a new blood bag container, in which 20 blood bags can be irradiated within 30 minutes.

read more
Radio Immuno Therapy

Radio Immuno Therapy

Study to improve the cure rates of patients by the direct in the tumor mass administration of radioactive labeled antibodies of the IgM.

read more